REVEAL GENOMICS® HER2DX® Genomic Test to Be Validated in Pivotal ECOG-ACRIN CompassHER2 pCR Trial in HER2+ Breast Cancer
14.5.2024 15:05:00 EEST | Business Wire | Press release
REVEAL GENOMICS, S.L., a Barcelona-based biotechnology start-up seeking to revolutionize precision oncology through biomarker innovation, today announced the forthcoming prospective validation of its groundbreaking diagnostic tool HER2DX® within the framework of the ongoing CompassHER2 pCR Trial. This study is led by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), a scientific organization that designs and conducts cancer research involving adults who have or are at risk of developing cancer, comprising nearly 1400 member institutions in the United States and around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240509117263/en/
The CompassHER2 pCR Trial (also EA1181) is a single-arm phase II neoadjuvant study that successfully enrolled 2175 patients with stage II or IIIa HER2-positive (HER2+) breast cancer. Now in follow-up, this trial seeks to determine if it is safe to omit adjuvant chemotherapy after surgery for patients with a pathologic complete response (pCR) after 3 months of pre-operative treatment with standard THP (single-agent taxane chemotherapy plus trastuzumab and pertuzumab [HP], both targeted drugs). If testing shows pCR at the time of surgery, patients will then complete a year of HP plus hormonal therapy and radiation, if indicated.
If the study's results validate this approach, it would allow patients to have fewer side effects and better quality of life. The neoadjuvant setting offers the opportunity to use pCR as a functional biomarker to identify patients with excellent outcomes and refine treatment to maximize benefit and minimize toxicity. The primary objective of the trial is 3-year recurrence-free survival, and pCR is a secondary endpoint.
In this collaboration, the CompassHER2 pCR Trial protocol has been amended to include the evaluation of the HER2DX® genomic test as a key secondary correlative endpoint. HER2DX® pCR-score and HER2DX® risk-score will be analyzed in baseline pre-treatment samples from most trial participants, linking these scores directly to patient outcomes.
The principal investigator of the CompassHER2 pCR Trial, Dr. Nadine M. Tung, commented, "Integrating HER2DX®'s predictive capabilities into our trial represents a significant opportunity in our quest to tailor treatments to the individual, not just the cancer type. If proven and validated, this assay could fundamentally change our approach to treating HER2-positive breast cancer."
Previous retrospective validation involving 765 patients with early-stage HER2+ breast cancer who received neoadjuvant therapy highlighted the HER2DX® pCR-score's ability to distinguish patients with a high pCR rate of 80-90% after treatment with single taxane, trastuzumab, and pertuzumab.
REVEAL GENOMICS' CEO, Patricia Villagrasa, added, "The inclusion of HER2DX® in the CompassHER2 pCR Trial is a testament to our commitment to advancing breast cancer treatment. By providing a more nuanced understanding of HER2-positive cancers, HER2DX® will play a crucial role in shaping the future of personalized therapy and improving patient outcomes."
HER2DX® in the CompassHER2 pCR Trial: Guiding the way to personalized medicine
The inclusion of HER2DX® in the CompassHER2 pCR Trial seeks to corroborate these initial findings, providing Level 1 evidence to support the selection of an optimized therapy regimen. Specifically, it seeks to validate the use of a single taxane-based regimen over traditional multi-agent chemotherapy, potentially revolutionizing the treatment approach for HER2-positive breast cancer by enabling more personalized, less intensive treatment strategies.
This pivotal collaboration represents a significant step towards personalized medicine in the management of early-stage HER2-positive breast cancer.
About HER2DX®️
HER2DX®️ is the world’s first diagnostic test formulated specifically for HER2+ breast cancer. Marketed by REVEAL GENOMICS®️ since January 2022, HER2DX® is a standardized 27-gene expression test for patients with early-stage HER2+ breast cancer.
HER2DX®️ is a prognostic, predictive assay based on clinical and genomic data. The test integrates clinical information (i.e. tumor size and nodal status) with biological information tracking immune response, luminal differentiation, tumor cell proliferation, and expression of the HER2 17q12-21 chromosomal amplicon, including the ERBB2 gene.
HER2DX®️ predicts:
- Risk of relapse score (high vs. low): the risk of recurrence in patients with newly diagnosed HER2+ breast cancer.
- pCR likelihood score (high vs. medium vs. low): the likelihood of a patient responding to anti-HER2-based treatment before surgery.
- ERBB2 score (high vs. medium vs. low): the quantitative expression of ERBB2 mRNA across HER2-negative, HER2-low and HER2+ breast cancer.
About ECOG-ACRIN
ECOG-ACRIN is renowned for advancing precision medicine and biomarker research through its leadership of major clinical trials that integrate cutting-edge genomic approaches. Through the CompassHER2 (COMprehensive use of Pathologic response ASSessment to escalate or de-escalate therapy in HER2-positive breast cancer) Trial Program, ECOG-ACRIN is collaborating with the Alliance for Clinical Trials in Oncology to investigate the optimization of therapy in patients with HER2+ breast cancer. The CompassHER2 pCR Trial (NCT04266249) was the first to open in this program, funded by the National Cancer Institute, part of the US National Institutes of Health.
Web: www.ecog-acrin.org, X: @eaonc. Other: Facebook, LinkedIn, and Instagram.
About REVEAL GENOMICS ®️
REVEAL GENOMICS, S.L. is a biotechnology start-up seeking to change the way biomarkers are used in oncology. It is focused on developing innovative diagnostic tools to define the best therapeutic options for patients with cancer. The company uses pioneering techniques, sophisticated computer applications, and machine learning to reveal new cancer research data.
REVEAL GENOMICS, S.L. is a spin-off company of Hospital Clínic of Barcelona, IDIBAPS, University of Barcelona (U.B.), and Vall d’Hebron Institute of Oncology (VHIO).
REVEAL GENOMICS® and HER2DX® are registered trademarks of REVEAL GENOMICS, S.L.
Web: www.reveal-genomics.com. X: @revealgenomics
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240509117263/en/
Contact information
Further information: Adriana Herrera, aherrera@reveal-genomics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BanyanGlobal Family Business Advisors Named Family Business Advisory Practice of the Year at the STEP Private Client Awards for the Fourth Time14.10.2026 16:05:00 EEST | Press release
BanyanGlobal Family Business Advisors ("Banyan") has been named Family Business Advisory Practice of the Year at the 21st annual STEP Private Client Awards, one of the most respected international honors in the private client profession. It is the fourth time Banyan has won the category, following wins in 2018, 2020 and 2021. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261013883351/en/ Kelly Greig, STEP Board Member and Dennis Jaffe, BanyanGlobal Family Business Advisors at the awards ceremony. BanyanGlobal won the Family Business Advisory Practice of the Year at the 21st Annual STEP Private Client Awards. The independent judging panel singled out Banyan's approach: "BanyanGlobal Family Business Advisors has redefined family business advisory by combining governance with helping families build skills and confidence for long-term ownership. Its innovative approach and long-standing client relationships helped make it the s
Telekom Srbija Group Expands AI Investment and Strengthens U.S. Technology Partnerships14.10.2026 16:02:00 EEST | Press release
Following the October 1 agreement between Serbia and the United States to strengthen cooperation in artificial intelligence (AI), Telekom Srbija Group is expanding its AI investment and deepening relationships with leading U.S. technology companies as part of its strategy to develop the next generation digital services. As part of these efforts, Telekom Srbija Group has engaged with the U.S. State Department, Department of Commerce and Export-Import Bank to explore opportunities for technology cooperation and project financing, with the ambition of becoming a preferred regional partner for U.S. companies. “Artificial intelligence represents one of the greatest opportunities for the future of telecommunications and digital services,” said Vladimir Lučić, CEO of Telekom Srbija Group. “We have been investing in this technology for several years, and our focus is now on accelerating its practical application. By combining AI innovation with our expanding 5G infrastructure and international
Wolters Kluwer names Alberto de Benito Aznar General Manager of Audit & Assurance14.10.2026 16:00:00 EEST | Press release
Wolters Kluwer, a global leader in professional information, software solutions and services, today announced the appointment of Alberto de Benito Aznar as General Manager of its Audit & Assurance business, part of the Corporate Performance & ESG division. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014786222/en/ De Benito Aznar returns to a business and market he knows well. He began his Wolters Kluwer career more than 10 years ago in Corporate Strategy and subsequently led operations for Audit & Assurance before serving most recently as General Manager of Corporate Tax. “Alberto brings a strong combination of strategic, operational and commercial leadership to Audit & Assurance,” said Maria Montenegro, CEO of Corporate Performance & ESG at Wolters Kluwer. “His leadership of Corporate Tax, combined with his previous experience in Audit & Assurance, gives him a valuable perspective as we build on TeamMate’s strong posi
Lenovo Uncovers What Happens When Entrepreneurs Look Beyond Borders for Support14.10.2026 16:00:00 EEST | Press release
Today, Lenovo debuts the first episode of its new documentary series from Backing Every Business, its global initiative designed to connect small businesses with the people, technology and support they need to grow and thrive. The series features five businesses participating in Twinning, Lenovo’sprogram that brings small business founders from around the world together, connecting them through mentorship across shared growth goals, access to resources including technology, AI training, funding designed to help address real business challenges and turn new ideas into action. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014736241/en/ The four-part series follows entrepreneurs from Japan, Mexico, the U.K. and the U.S. as they step inside one another’s businesses, experience unfamiliar industries and cultures and share the knowledge they have gained from building their own businesses. A meeting between strangers evolves in
Airship Achieves ISO 42001 Certification, Clearing the Path for Responsible Enterprise AI14.10.2026 16:00:00 EEST | Press release
Airship, the mobile-first customer experience company, today announced it has achieved ISO 42001 certification, the global benchmark for Artificial Intelligence Management Systems (AIMS). Certified following an independent audit by A-LIGN, Airship is among the first in the CX industry to earn this standard across its platform. This certification provides enterprise brands with an independently verified foundation to scale AI-driven customer journeys—eliminating procurement hurdles while supporting compliance, data privacy, and EU AI Act readiness. Solving the Enterprise AI Paradox Enterprise product and marketing leaders face mounting pressure to innovate with AI, yet fears of data leaks, hallucinations, and regulatory non-compliance continue to stall adoption. Airship’s ISO 42001 certification addresses those concerns: an independent auditor confirmed that Airship governs its AI capabilities through a documented, tested, and continually improving management system. According to Forres
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom